Stockreport

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Scleros...

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF therapy, CM-101, for the treatment of primary sclerosing cholangitis (PSC), a rare liver disease. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track design [Read more]